Diffuse large B-cell lymphoma trials in Australia

In Australia 20 Also abroad 346

20 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Where
Nedlands, Richmond
Age
18 years and over
People
180 worldwide
Run by
ModeX Therapeutics, An OPKO Health Company
See details and how to joinNCT07249905
Phase 3Taking people
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Where
Auchenflower, Benowa, East Melbourne, Liverpool, Waratah
Age
18 years and over
People
904 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00
Phase 3Taking people
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Where
Douglas, Melbourne
Age
18 years and over
People
400 worldwide
Run by
Lyell Immunopharma, Inc.
See details and how to joinNCT07188558
Phase 2/3Taking people
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Where
Ballarat, Perth, Townsville
Age
18 years and over
People
290 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00
Phase 1Taking people
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Where
Adelaide, Hobart, Perth, Westmead
Age
18 years and over
People
140 worldwide
Run by
Iksuda Therapeutics Ltd.
See details and how to joinNCT05365659
Phase 1Taking people
A Study of ARC-02 in B-cell NHL
Where
Clayton, Melbourne, Nedlands, Southport
Age
18 years and over
People
140 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Brisbane, Melbourne, Randwick
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 2Taking people
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Where
Auchenflower, Clayton, Fitzroy, Heidelberg, Hobart, Nedlands, Waratah
Age
18 years and over
People
250 worldwide
Run by
Allogene Therapeutics
See details and how to joinNCT06500273
Phase 3Taking people
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Where
Adelaide, Ballarat, Melbourne, Perth, Townsville
Age
18 years and over
People
1,046 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00
Phase 2Taking people
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Where
East Melbourne
Age
18 years and over
People
130 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00
Phase 1Taking people
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Where
Adelaide, Melbourne, Sydney, Woolloongabba
Age
18 years and over
People
280 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07195916 · EU 2025-523130-11-00
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Concord, Fitzroy, Heidelberg, Melbourne, Nedlands, Waratah, West Perth, Woolloongabba
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 1/2Taking people
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Where
Melbourne, Nedlands, Perth
Age
18 years and over
People
270 worldwide
Run by
Lyell Immunopharma, Inc.
See details and how to joinNCT05826535
Phase 2Not yet taking people in Australia
Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Where
Bedford Park, Douglas, Heidelberg, Murdoch, Woolloongabba
Age
18 years and over
People
40
Run by
Olivia Newton-John Cancer Research Institute
See details and how to joinNCT07634289
No phaseTaking people
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
Where
Kingswood, Malvern, Waratah
Age
18 years and over
People
700 worldwide
Run by
AbbVie
See details and how to joinNCT06830759
Phase 1Taking people
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Where
Bedford Park, Buderim, Darlinghurst, Southport, Subiaco, Wollongong, Woolloongabba
Age
18 years and over
People
168 worldwide
Run by
OncoNano Medicine, Inc.
See details and how to joinNCT06022029
Phase 3Taking people
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
Where
Albury, Camperdown, Coffs Harbour, Concord, Cudgen, Garran, Hobart, Liverpool, Melbourne, Murdoch, Orange, Perth, Port Macquarie, Randwick, St Leonards, Sunshine Coast, Waratah, Westmead
Age
75 years and over
People
300 worldwide
Run by
Nordic Lymphoma Group
See details and how to joinNCT04332822 · EU 2022-502887-19-00
Phase 2Taking people
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
Where
Melbourne
Age
18 years and over
People
39
Run by
Australasian Leukaemia and Lymphoma Group
See details and how to joinNCT06287398
Phase 2Taking people
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Adelaide, Melbourne, Westmead
Age
18 years and over
People
102 worldwide
Run by
ImmunoVaccine Technologies, Inc. (IMV Inc.)
See details and how to joinNCT04920617
Phase 1/2Taking people
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Where
Adelaide, Box Hill, Geelong, Perth
Age
18 years and over
People
84 worldwide
Run by
Kartos Therapeutics, Inc.
See details and how to joinNCT04502394